ArticleAnnals of hematology2018

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.

Alexander Egle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.